Overview

Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT

Status:
COMPLETED
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Low-dose post-transplant cyclophosphamide have demonstrated therapeutic efficacy in allogeneic stem cell transplants which is comparable with the standard dose and also facilitates early hematological recovery.
Phase:
PHASE2
Details
Lead Sponsor:
Hospital Universitario Dr. Jose E. Gonzalez
Treatments:
Cyclophosphamide